The guidance presented here is for informational purposes only and is not intended to provide
reimbursement or legal advice. AbbVie does not guarantee that the use of any information
provided will result in coverage or payment by any third-party payer. You are responsible
for the submission based on your clinical judgment.
LUPRON DEPOT-PED 45 MG FOR 6-MONTH ADMINISTRATION1
LUPRON DEPOT-PED is indicated for the treatment of pediatric patients with Central Precocious Puberty (CPP).
In the clinical study for LUPRON DEPOT-PED 45 mg for 6-month administration, the most common (≥4%) adverse reactions were:
Please see additional Important Safety Information below.
Please see full Prescribing Information.
Reference: 1. LUPRON DEPOT-PED [package insert]. North Chicago, IL: AbbVie Inc.
US-LUPR-250262
You are leaving this website. Links to all outside websites are provided as a convenience to our visitors and do not imply an endorsement or recommendation by AbbVie. AbbVie accepts no responsibility or liability for the content or services of other websites.